Hemogenyx Pharmaceuticals plc...is pleased to announce that it has raised £2,500,000 from a consortium of private investors through a direct subscription for 313,333 new ordinary shares in the Company at a price of £7.50 per share. (ACCESS Newswire) - Feb 10, 2026 - "The net proceeds of this fundraise will be dedicated primarily to the continuation of the Phase I clinical trials for the Company's Chimeric Antigen Receptor T-cell therapy ('HG-CT-1'), aimed at treating relapsed/refractory acute myeloid leukemia ('R/R AML') both in adults and also now in children....In addition, the Company has received clearance from the U.S. Food and Drug Administration ('FDA') to initiate a Phase I clinical trial in pediatric patients aged 12-18 years."
Financing • IND • Acute Myelogenous Leukemia
|